Avego BioScience Capital
Alpharetta, Georgia, United StatesFounded 2015
Avego BioScience Capital focuses on mid-to-late stage venture financings for life sciences companies. Their strategy is evidence-based, prioritizing proprietary technologies and scientific advancements with the potential for "best- or first-in-class" products.
100% of their portfolio is in Biotech & Life Sciences. Deal activity increased 100% year-over-year (2 deals in the last 12 months). Their most common stage is series-c (50% of deals). Average disclosed round size is $153.1M (across 4 rounds with reported amounts).
Portfolio
4
Fund Size
$68.7M
Top Stage
Series C
Last 12 Mo
2
Portfolio Breakdown
Stage Distribution
Investment Activity
DealsAvg Round Size
Portfolio
4 investments
| Company | Round | Amount | Date |
|---|---|---|---|
| TTRexBio | Series C | $50M | Jan 2026 |
 MapLight Therapeutics | Series D | $372.5M | Jul 2025 |
 Evommune, Inc. | Series C | $115M | Oct 2024 |
 Antios Therapeutics | Series B | $75M | Nov 2021 |
Top Co-Investors
Delos Capital2 shared
RA Capital Management2 shared
Forbion1 shared
Sanofi Ventures1 shared
EPIQ Capital Group1 shared
Sixty Degree Capital1 shared
Pontifax1 shared
Soleus Capital1 shared
Amzak Health1 shared
LifeSci Venture Partners1 shared
Sectoral Asset Management1 shared
B Capital1 shared
Marshall Wace1 shared
Longwood Fund1 shared
RTW Investments1 shared
Beiersdorf1 shared
Pivotal bioVenture Partners1 shared
EQT Life Sciences1 shared
Andera Partners1 shared
Last updated: 10 April 2026